Oxidative and Nitrosative Stress in Major Depressive Disorder: A Case Control Study

Somani, Aditya; Singh, Abhishek Kumar; Gupta, Bandna; Nagarkoti, Sheela; Dalal, Pronob Kumar; Dikshit, Madhu

doi:10.3390/brainsci12020144

Cited by 21 publications

(17 citation statements)

References 67 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies indicate that MPO expression at both mRNA and protein levels is increased in depressed patients [ 36 , 37 ]. Similarly, Somani et al showed increased MPO activity in this group of patients [ 38 ]. Our results contradict these findings, since expression of MPO was significantly lower in our patients with depressive disorders than in the control group, both at the mRNA and protein levels.…”

Section: Discussionsupporting

confidence: 53%

Expression of PON1, PON2, PON3 and MPO Genes in Patients with Depressive Disorders

Bliźniewska-Kowalska

Gałecki

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Taking into account the role of oxidative stress in neurodegeneration, we sought to evaluate the expression of genes for select enzymes with antioxidant properties (paraoxonases PON1, PON2 and PON3 and myeloperoxidase MPO) at the mRNA and protein levels in patients with depressive disorders. We further sought to determine the impact of oxidative stress in the etiopathogenesis of this group of mood disorders. Methods: A total of 290 subjects (190 depressed patients, 100 healthy controls) took part in the study. Sociodemographic and clinical data were collected. The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS). Venous blood was collected. RT-PCR was used to assess gene expression at the mRNA level, while enzyme-linked immunosorbent assay (ELISA) was used to assess gene expression at the protein level. Results: The expression of the PON2 and PON3 genes at the protein level was significantly higher in depressive patients than in healthy controls. mRNA expression of the PON1, PON2 and PON3 genes was slightly higher in patients with depressive disorders than in the control group, however, this relationship was not statistically significant. On the other hand, the expression of the MPO gene at both mRNA and protein levels was significantly lower in patients with depressive disorder than in the control group. Conclusions: Our results are not in agreement with many studies on enzymes involved in maintaining oxidative balance. Our findings may not support the utility of paraoxonases (PON) or myeloperoxidase (MPO) as promising biomarker candidates of depression pending larger and well controlled studies.

show abstract

Section: Discussionsupporting

confidence: 53%

Expression of PON1, PON2, PON3 and MPO Genes in Patients with Depressive Disorders

Bliźniewska-Kowalska

Gałecki

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Mitochondrial disruption also generates free radicals and oxidative stress. In MDD, oxidative and nitrosative stress markers are increased, while antioxidant capacity is decreased [ 158 – 160 ]. Moreover, positive correlations with illness duration suggest a progressive course of mitochondrial dysfunction and oxidative damage with the disease [ 161 ].…”

Section: Molecular Pathways and Systemsmentioning

confidence: 99%

Molecular pathways of major depressive disorder converge on the synapse

et al. 2022

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a psychiatric disease of still poorly understood molecular etiology. Extensive studies at different molecular levels point to a high complexity of numerous interrelated pathways as the underpinnings of depression. Major systems under consideration include monoamines, stress, neurotrophins and neurogenesis, excitatory and inhibitory neurotransmission, mitochondrial dysfunction, (epi)genetics, inflammation, the opioid system, myelination, and the gut-brain axis, among others. This review aims at illustrating how these multiple signaling pathways and systems may interact to provide a more comprehensive view of MDD’s neurobiology. In particular, considering the pattern of synaptic activity as the closest physical representation of mood, emotion, and conscience we can conceptualize, each pathway or molecular system will be scrutinized for links to synaptic neurotransmission. Models of the neurobiology of MDD will be discussed as well as future actions to improve the understanding of the disease and treatment options.

show abstract

“…The interaction of the PDZ2-domain of PSD-95 with nNOS (neuronal nitric oxide synthase) plays a vital role in this process [ 96 , 98 ]. nNOS is one of the three isoforms of the NOS enzyme and is widely distributed in the CNS and has also been demonstrated in human neutrophils [ 99 ]. Nikonenko et al showed that both small interfering RNA (siRNA)-mediated knockdown of nNOS and pharmacological blockade by administration of L-N G -nitroarginine methyl ester (L-NAME, NOS inhibitor) result in the inhibition of multi-innervated spines formation, thus demonstrating the role of PSD-95 and nNOS as essential factors for synapse building [ 98 ].…”

Section: The Role Of Postsynaptic Density Proteins In the Excitatory ...mentioning

confidence: 99%

“…It has been observed that the level of SHANK3 in peripheral blood mononuclear cells (PBMCs) correlates with treatment response among women with MDD, indicating the potential employment of SHANK3 as a marker of antidepressant response [ 124 ]. Although some studies suggest a genetic predisposition to DDs, Somani et al showed that neutrophils of drug-naïve MDD patients significantly have higher nNOS mRNA expression, but no such correlation was found among first-degree relatives of these patients [ 99 ]. In contrast, the locus coeruleus showed reduced nNOS protein immunoreactivity, which was absent in the cerebellum [ 122 ].…”

Section: Alterations In Postsynaptic Density Proteins In Depressive D...mentioning

confidence: 99%

Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders

Samojedny

Czechowska

Pańczyszyn-Trzewik

et al. 2022

IJMS

View full text Add to dashboard Cite

Depressive disorders (DDs) are an increasingly common health problem that affects all age groups. DDs pathogenesis is multifactorial. However, it was proven that stress is one of the most important environmental factors contributing to the development of these conditions. In recent years, there has been growing interest in the role of the glutamatergic system in the context of pharmacotherapy of DDs. Thus, it has become increasingly important to explore the functioning of excitatory synapses in pathogenesis and pharmacological treatment of psychiatric disorders (including DDs). This knowledge may lead to the description of new mechanisms of depression and indicate new potential targets for the pharmacotherapy of illness. An excitatory synapse is a highly complex and very dynamic structure, containing a vast number of proteins. This review aimed to discuss in detail the role of the key postsynaptic proteins (e.g., NMDAR, AMPAR, mGluR5, PSD-95, Homer, NOS etc.) in the excitatory synapse and to systematize the knowledge about changes that occur in the clinical course of depression and after antidepressant treatment. In addition, a discussion on the potential use of ligands and/or modulators of postsynaptic proteins at the excitatory synapse has been presented.

show abstract

Oxidative and Nitrosative Stress in Major Depressive Disorder: A Case Control Study

Cited by 21 publications

References 67 publications

Expression of PON1, PON2, PON3 and MPO Genes in Patients with Depressive Disorders

Expression of PON1, PON2, PON3 and MPO Genes in Patients with Depressive Disorders

Molecular pathways of major depressive disorder converge on the synapse

Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders

Contact Info

Product

Resources

About